GSTM1 null genotype underpins recurrence of NF2 meningiomas
IntroductionMeningiomas are the most common primary central nervous system (CNS) tumor in adults, comprising one-third of all primary adult CNS tumors. Although several recent publications have identified molecular alterations in meningioma including characteristic mutations, copy number alterations...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1506708/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061181703684096 |
|---|---|
| author | Anthony C. Johnson Anthony C. Johnson Erdyni N. Tsitsikov Khanh P. Phan Jeffrey A. Zuccato Andrew M. Bauer Christopher S. Graffeo Sanaa Hameed Tressie M. Stephens Yufeng Liu Gavin P. Dunn Alla V. Tsytsykova Pamela S. Jones Ian F. Dunn |
| author_facet | Anthony C. Johnson Anthony C. Johnson Erdyni N. Tsitsikov Khanh P. Phan Jeffrey A. Zuccato Andrew M. Bauer Christopher S. Graffeo Sanaa Hameed Tressie M. Stephens Yufeng Liu Gavin P. Dunn Alla V. Tsytsykova Pamela S. Jones Ian F. Dunn |
| author_sort | Anthony C. Johnson |
| collection | DOAJ |
| description | IntroductionMeningiomas are the most common primary central nervous system (CNS) tumor in adults, comprising one-third of all primary adult CNS tumors. Although several recent publications have identified molecular alterations in meningioma including characteristic mutations, copy number alterations, and gene expression signatures, our understanding of the drivers of meningioma recurrence is limited.ObjectiveTo identify gene expression signatures of 1p-22q-NF2- meningioma recurrence, with concurrent biallelic inactivation of NF2 and loss of chr1p that are heterogenous but enriched for recurrent meningiomas.MethodsTranscriptomic alterations present in recurrent versus primary 1p-22q-NF2- meningiomas were identified using RNA sequencing (RNA-seq) data in a clinically annotated cohort.ResultsRecurrent 1p-22q-NF2- meningiomas were enriched for a newly identified GSTM1 null genotype compared to primary meningiomas that showed variable GSTM1 expression and independent external validation was performed.ConclusionsThe GSTM1 null genotype is a novel biomarker of 1p-22q-NF2- meningioma recurrence that resolves heterogeneity in existing meningioma subtypes and may be used to guide future clinical management decisions on extent of treatment to improve patient outcomes. |
| format | Article |
| id | doaj-art-ae07ec22ef2b4062b73fde6b7b0ce77c |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ae07ec22ef2b4062b73fde6b7b0ce77c2025-08-20T02:50:19ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.15067081506708GSTM1 null genotype underpins recurrence of NF2 meningiomasAnthony C. Johnson0Anthony C. Johnson1Erdyni N. Tsitsikov2Khanh P. Phan3Jeffrey A. Zuccato4Andrew M. Bauer5Christopher S. Graffeo6Sanaa Hameed7Tressie M. Stephens8Yufeng Liu9Gavin P. Dunn10Alla V. Tsytsykova11Pamela S. Jones12Ian F. Dunn13Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesDepartment of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesDepartment of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesIntroductionMeningiomas are the most common primary central nervous system (CNS) tumor in adults, comprising one-third of all primary adult CNS tumors. Although several recent publications have identified molecular alterations in meningioma including characteristic mutations, copy number alterations, and gene expression signatures, our understanding of the drivers of meningioma recurrence is limited.ObjectiveTo identify gene expression signatures of 1p-22q-NF2- meningioma recurrence, with concurrent biallelic inactivation of NF2 and loss of chr1p that are heterogenous but enriched for recurrent meningiomas.MethodsTranscriptomic alterations present in recurrent versus primary 1p-22q-NF2- meningiomas were identified using RNA sequencing (RNA-seq) data in a clinically annotated cohort.ResultsRecurrent 1p-22q-NF2- meningiomas were enriched for a newly identified GSTM1 null genotype compared to primary meningiomas that showed variable GSTM1 expression and independent external validation was performed.ConclusionsThe GSTM1 null genotype is a novel biomarker of 1p-22q-NF2- meningioma recurrence that resolves heterogeneity in existing meningioma subtypes and may be used to guide future clinical management decisions on extent of treatment to improve patient outcomes.https://www.frontiersin.org/articles/10.3389/fonc.2024.1506708/fullmeningiomarecurrentCNS tumorstranscriptome profilinggene expressionNF2 |
| spellingShingle | Anthony C. Johnson Anthony C. Johnson Erdyni N. Tsitsikov Khanh P. Phan Jeffrey A. Zuccato Andrew M. Bauer Christopher S. Graffeo Sanaa Hameed Tressie M. Stephens Yufeng Liu Gavin P. Dunn Alla V. Tsytsykova Pamela S. Jones Ian F. Dunn GSTM1 null genotype underpins recurrence of NF2 meningiomas Frontiers in Oncology meningioma recurrent CNS tumors transcriptome profiling gene expression NF2 |
| title | GSTM1 null genotype underpins recurrence of NF2 meningiomas |
| title_full | GSTM1 null genotype underpins recurrence of NF2 meningiomas |
| title_fullStr | GSTM1 null genotype underpins recurrence of NF2 meningiomas |
| title_full_unstemmed | GSTM1 null genotype underpins recurrence of NF2 meningiomas |
| title_short | GSTM1 null genotype underpins recurrence of NF2 meningiomas |
| title_sort | gstm1 null genotype underpins recurrence of nf2 meningiomas |
| topic | meningioma recurrent CNS tumors transcriptome profiling gene expression NF2 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1506708/full |
| work_keys_str_mv | AT anthonycjohnson gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT anthonycjohnson gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT erdynintsitsikov gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT khanhpphan gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT jeffreyazuccato gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT andrewmbauer gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT christophersgraffeo gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT sanaahameed gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT tressiemstephens gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT yufengliu gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT gavinpdunn gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT allavtsytsykova gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT pamelasjones gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas AT ianfdunn gstm1nullgenotypeunderpinsrecurrenceofnf2meningiomas |